Floatz logo

Humax-Cd20

Demyelinating Diseases of the Central Nervous System

Tianjin Medical University General Hospitalmonoclonal_antibodyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Demyelinating Diseases of the Central Nervous System cohort.

Asset / SponsorPhaseRating
CLEMASTIN
University of California, San Francisco
Phase 1/2CCC
OPICINUMAB
Biogen
Phase 1CC
Calculus Bovis Sativus
Tongji Hospital
N/ANR

Same molecule, other indications

Humax-Cd20 is also rated in:

B-cell chronic lymphocytic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
74 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →